Skip to content

Research use only. Not for human or veterinary use. We don’t sell products. Read more

GLP-1 & metabolic

Retatrutide Price Comparison

Triple GIP, GLP-1 and glucagon receptor agonist in late-stage clinical trials.

Also referred to as: LY3437943 · Triple agonist · Retatrutide (GLP-1/GIP/Glucagon receptor tri-agonist) · Triple GLP-1/GIP/Glucagon Agonist

Lowest in stock£1.00/mg· Peptides Kent

UK supplier comparison

Use the filters to pick a size and presentation (vial, pen or serum) and compare like for like, or view every size on a £ per mg basis. Delivery is shown separately because it varies by supplier and order size. Offers whose outbound link failed our last check stay listed but rank below working links.

Best price
£1.00/mg

lowest in stock, working link

Average
£2.20/mg

across 5 in-stock offers

Highest
£3.33/mg

highest in stock

You could save
70%

best vs highest

Showing normalised £ per mg across all sizes. Sorted: lowest £/mg first. Stats use in-stock offers only.

SupplierSizePrice£ / mgStockLink healthDeliveryQuality (claimed)Visit

United Kingdom

60 mg vial£60.00£1.00In stock

Checked 2026-10-23

Link OK
Free UKVisit Peptides Kent

United Kingdom

30 mg vial£50.00£1.67In stock

Checked 2026-10-23

Link OK
Free UKVisit Peptides Kent

United Kingdom

60 mg pen£120.00£2.00In stock

Checked 2026-10-23

Link OK
Free UKVisit Peptides Kent

United Kingdom

10 mg vial£30.00£3.00In stock

Checked 2026-10-23

Link OK
Free UKVisit Peptides Kent

United Kingdom

30 mg pen£100.00£3.33In stock

Checked 2026-10-23

Link OK
Free UKVisit Peptides Kent

Prices are set by independent suppliers and may change. Quality and CoA labels are self-reported claims — not verified by PeptideCompare. PeptideCompare does not sell or supply products and cannot vouch for quality, legality or availability. For in-vitro research only — not for human or veterinary use.

For in-vitro laboratory research only

Retatrutide is listed here as a research material. It is not for human or veterinary consumption, and nothing on this page is medical advice or dosing guidance. PeptideCompare is paid by flat supplier fees — never by sales commission or referral — so a price ranks by its number, not by who pays. We do not sell, test or verify any product, and quality or CoA labels are suppliers’ own claims. Always check the final price, documentation and legality with the supplier yourself.

Research profile

About Retatrutide in the lab

An investigational molecule designed to act on three related class-B GPCRs. Laboratory work centres on comparative receptor pharmacology and analytical characterisation.

Proposed mechanism

A single acylated peptide that activates GIP, GLP-1 and glucagon receptors. The incretin components affect insulin secretion and satiety, while glucagon-receptor activity raises energy expenditure and hepatic fat oxidation in models.

Structure note

Engineered 39-residue backbone with non-natural amino acids and a fatty-diacid side chain; published masses vary slightly by source.

Amino-acid sequence (one-letter)

HUEGTFTSDVSSYLEGQAAKEFIAWLVRGRGPSSGAPPPS

Typical research themes

  • Multi-receptor pharmacology
  • Class B GPCR assays
  • Mass-spectrometry characterisation

Regulatory note

This is an investigational compound with no marketing authorisation. Research-grade material is not for human or veterinary use.

Key references

  1. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. · The New England journal of medicine (2023)

This profile is a short, general summary of publicly discussed science. It is not exhaustive, not peer-reviewed by PeptideCompare, and is not medical advice. PeptideCompare provides no dosing, protocol or usage guidance — nothing here is for human or veterinary use.

More ways to compare

← Back to catalogue